Juxtapid is a first-in-class microsomal triglyceride transfer protein (MTP) inhibitor that reduces production of LDL-C that accumulates aggressively in patients with HoFH.*
Learn more about how Juxtapid works and why adding Juxtapid to your adult patient’s treatment regimen may make sense.
*Juxtapid is indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
Limitations of Use:
- The safety and effectiveness of Juxtapid have not been established in patients with hypercholesterolemia who do not have HoFH.
- The effect of Juxtapid on cardiovascular morbidity and mortality has not been determined.
Because of the risk of hepatotoxicity, Juxtapid is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Juxtapid REMS Program. Learn more about the REMS program here.
Review the Phase 3 clinical trial here.
Examine the safety of Juxtapid, including the risk of hepatotoxicity here.